5. Imaging techniques in diagnostic approaches

Claudio G. De Angelis, Flavio Crippa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Despite the considerable technological advances in imaging modalities which have occurred over the last years, EUS remains one of the most reliable and accurate technique for the study of gastroenteropancreatic neuroendocrine tumors. More specifically, EUS can detect very small lesions, assess the local extent and lymph node involvement and biopsy the lesion for cytophatological confirmation (EUS-FNA). In addition, nuclear medicine imaging has a relevant role in the evaluation of NET. However, its performance depends on series of patient-specific features (lesion size and uptake, depth and other anatomic features; metabolic activity, receptor expression, affinity and vacancy, tissue specificity) and technical features (choice of tracer, administered dose, and physical half-life; instrument sensitivity, acquisition technique, reader experience). In particular, current data show that PET/CT has greater intrinsic resolution and sensitivity than SPECT or SPECT/CT images resulting in improved tumor detection. However, the PET tracer of choice has not yet been identified. 18F-FDG has proved to be useful as indicator of tumor aggressiveness rather than detection of extent of disease, and 68Ga-DOTA-TOC has demonstrated good results in clinical trials. 11C-5HTP has performed well in limited trials, but the 20-min half life of 11C precludes widespread availability. Better information concerning biodistribution and further comparative data of these agent in larger clinical trials are warranted.

Original languageEnglish
Pages (from-to)817-822
Number of pages6
JournalTumori
Volume96
Issue number5
Publication statusPublished - Sep 2010

Fingerprint

Half-Life
Clinical Trials
Endoscopic Ultrasound-Guided Fine Needle Aspiration
Organ Specificity
Nuclear Medicine
Fluorodeoxyglucose F18
Single-Photon Emission-Computed Tomography
Neoplasms
Lymph Nodes
Biopsy
Single Photon Emission Computed Tomography Computed Tomography
Gastro-enteropancreatic neuroendocrine tumor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

De Angelis, C. G., & Crippa, F. (2010). 5. Imaging techniques in diagnostic approaches. Tumori, 96(5), 817-822.

5. Imaging techniques in diagnostic approaches. / De Angelis, Claudio G.; Crippa, Flavio.

In: Tumori, Vol. 96, No. 5, 09.2010, p. 817-822.

Research output: Contribution to journalArticle

De Angelis, CG & Crippa, F 2010, '5. Imaging techniques in diagnostic approaches', Tumori, vol. 96, no. 5, pp. 817-822.
De Angelis CG, Crippa F. 5. Imaging techniques in diagnostic approaches. Tumori. 2010 Sep;96(5):817-822.
De Angelis, Claudio G. ; Crippa, Flavio. / 5. Imaging techniques in diagnostic approaches. In: Tumori. 2010 ; Vol. 96, No. 5. pp. 817-822.
@article{15d6260ed0a44ead950ad4ea91b7eb97,
title = "5. Imaging techniques in diagnostic approaches",
abstract = "Despite the considerable technological advances in imaging modalities which have occurred over the last years, EUS remains one of the most reliable and accurate technique for the study of gastroenteropancreatic neuroendocrine tumors. More specifically, EUS can detect very small lesions, assess the local extent and lymph node involvement and biopsy the lesion for cytophatological confirmation (EUS-FNA). In addition, nuclear medicine imaging has a relevant role in the evaluation of NET. However, its performance depends on series of patient-specific features (lesion size and uptake, depth and other anatomic features; metabolic activity, receptor expression, affinity and vacancy, tissue specificity) and technical features (choice of tracer, administered dose, and physical half-life; instrument sensitivity, acquisition technique, reader experience). In particular, current data show that PET/CT has greater intrinsic resolution and sensitivity than SPECT or SPECT/CT images resulting in improved tumor detection. However, the PET tracer of choice has not yet been identified. 18F-FDG has proved to be useful as indicator of tumor aggressiveness rather than detection of extent of disease, and 68Ga-DOTA-TOC has demonstrated good results in clinical trials. 11C-5HTP has performed well in limited trials, but the 20-min half life of 11C precludes widespread availability. Better information concerning biodistribution and further comparative data of these agent in larger clinical trials are warranted.",
author = "{De Angelis}, {Claudio G.} and Flavio Crippa",
year = "2010",
month = "9",
language = "English",
volume = "96",
pages = "817--822",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - 5. Imaging techniques in diagnostic approaches

AU - De Angelis, Claudio G.

AU - Crippa, Flavio

PY - 2010/9

Y1 - 2010/9

N2 - Despite the considerable technological advances in imaging modalities which have occurred over the last years, EUS remains one of the most reliable and accurate technique for the study of gastroenteropancreatic neuroendocrine tumors. More specifically, EUS can detect very small lesions, assess the local extent and lymph node involvement and biopsy the lesion for cytophatological confirmation (EUS-FNA). In addition, nuclear medicine imaging has a relevant role in the evaluation of NET. However, its performance depends on series of patient-specific features (lesion size and uptake, depth and other anatomic features; metabolic activity, receptor expression, affinity and vacancy, tissue specificity) and technical features (choice of tracer, administered dose, and physical half-life; instrument sensitivity, acquisition technique, reader experience). In particular, current data show that PET/CT has greater intrinsic resolution and sensitivity than SPECT or SPECT/CT images resulting in improved tumor detection. However, the PET tracer of choice has not yet been identified. 18F-FDG has proved to be useful as indicator of tumor aggressiveness rather than detection of extent of disease, and 68Ga-DOTA-TOC has demonstrated good results in clinical trials. 11C-5HTP has performed well in limited trials, but the 20-min half life of 11C precludes widespread availability. Better information concerning biodistribution and further comparative data of these agent in larger clinical trials are warranted.

AB - Despite the considerable technological advances in imaging modalities which have occurred over the last years, EUS remains one of the most reliable and accurate technique for the study of gastroenteropancreatic neuroendocrine tumors. More specifically, EUS can detect very small lesions, assess the local extent and lymph node involvement and biopsy the lesion for cytophatological confirmation (EUS-FNA). In addition, nuclear medicine imaging has a relevant role in the evaluation of NET. However, its performance depends on series of patient-specific features (lesion size and uptake, depth and other anatomic features; metabolic activity, receptor expression, affinity and vacancy, tissue specificity) and technical features (choice of tracer, administered dose, and physical half-life; instrument sensitivity, acquisition technique, reader experience). In particular, current data show that PET/CT has greater intrinsic resolution and sensitivity than SPECT or SPECT/CT images resulting in improved tumor detection. However, the PET tracer of choice has not yet been identified. 18F-FDG has proved to be useful as indicator of tumor aggressiveness rather than detection of extent of disease, and 68Ga-DOTA-TOC has demonstrated good results in clinical trials. 11C-5HTP has performed well in limited trials, but the 20-min half life of 11C precludes widespread availability. Better information concerning biodistribution and further comparative data of these agent in larger clinical trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=78650441261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650441261&partnerID=8YFLogxK

M3 - Article

C2 - 21302638

AN - SCOPUS:78650441261

VL - 96

SP - 817

EP - 822

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -